{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:00:04Z","timestamp":1785218404767,"version":"3.55.0"},"reference-count":176,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3402000"],"award-info":[{"award-number":["2023YFC3402000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82322054"],"award-info":[{"award-number":["82322054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32521009"],"award-info":[{"award-number":["32521009"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Although chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in hematological malignancies, its therapeutic efficacy in solid tumors remains limited by several challenges, including insufficient tumor infiltration, T cell exhaustion and the immunosuppressive tumor microenvironment (TME). CRISPR\/Cas, a third-generation gene editing technology developed in recent years, is characterized by its simplicity and high efficiency. This technology has demonstrated broad application potential across multiple fields and has emerged as a powerful tool for improving CAR-T cell therapy. In this review, we summarize recent advances in the application of CRISPR\/Cas gene editing technology to enhance the antitumor activity of CAR-T cells against solid tumors. We also discuss the key challenges currently faced and systematically propose potential strategies for overcoming the limitations.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1910092","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:34:14Z","timestamp":1785216854000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rewriting CAR-T cell fate: CRISPR\/Cas gene editing for solid tumor therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Wenjing","family":"Liu","sequence":"first","affiliation":[{"name":"Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Gu","sequence":"additional","affiliation":[{"name":"Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Xie","sequence":"additional","affiliation":[{"name":"Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Du","sequence":"additional","affiliation":[{"name":"Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12032-023-02146-y","article-title":"Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy","volume":"40","author":"Dabas","year":"2023","journal-title":"Med Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological Malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2021.101304","article-title":"Advances in CAR design","volume":"34","author":"Heard","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2022","journal-title":"Future Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29123","article-title":"Tisagenlecleucel for treatment of children and young adults with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"68","author":"Si Lim","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2018.12.034","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"176","author":"Sade-Feldman","year":"2019","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau0135","article-title":"T cell stemness and dysfunction in tumors are triggered by a common mechanism","volume":"363","author":"Vodnala","year":"2019","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn2337","article-title":"KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection","volume":"387","author":"Fagerberg","year":"2025","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00568-0","article-title":"Transcriptional regulatory network for the establishment of CD8(+) T cell exhaustion","volume":"53","author":"Seo","year":"2021","journal-title":"Exp Mol Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01224-z","article-title":"Epigenetic regulation of T cell exhaustion","volume":"23","author":"Belk","year":"2022","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.146","article-title":"Epigenetic control of CD8(+) T cell differentiation","volume":"18","author":"Henning","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116129","article-title":"HDAC-targeting epigenetic modulators for cancer immunotherapy","volume":"265","author":"Cheng","year":"2024","journal-title":"Eur J Med Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1615\/critrevimmunol.2020033728","article-title":"DNA methylation in T-cell development and differentiation","volume":"40","author":"Correa","year":"2020","journal-title":"Crit Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.11218","article-title":"DNA methylation, its mediators and genome integrity","volume":"11","author":"Meng","year":"2015","journal-title":"Int J Biol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.035","article-title":"Mitochondrial dynamics controls T cell fate through metabolic programming","volume":"166","author":"Buck","year":"2016","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat5011","article-title":"CRISPR-Cas guides the future of genetic engineering","volume":"361","author":"Knott","year":"2018","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40364-024-00602-z","article-title":"CRISPR\/Cas-based CAR-T cells: production and application","volume":"12","author":"Song","year":"2024","journal-title":"biomark Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3149","article-title":"A split-Cas9 architecture for inducible genome editing and transcription modulation","volume":"33","author":"Zetsche","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat BioMed Eng"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0000000000000127","article-title":"The role of stroma in tumor development","volume":"21","author":"Werb","year":"2015","journal-title":"Cancer J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14521","article-title":"Tumor microenvironment in gastric cancers","volume":"111","author":"Oya","year":"2020","journal-title":"Cancer Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming TGF\u03b2-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-019-00744-5","article-title":"CD8(+) T cell exhaustion","volume":"41","author":"Kurachi","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0338","article-title":"Exhausted T cells and epigenetic status","volume":"17","author":"Zeng","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cells14050320","article-title":"Strategies to overcome antigen heterogeneity in CAR-T cell therapy","volume":"14","author":"Zhang","year":"2025","journal-title":"Cells"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-3784","article-title":"Modulation of target antigen density improves CAR T-cell functionality and persistence","volume":"25","author":"Ramakrishna","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2386187","article-title":"Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies","volume":"2018","author":"Sun","year":"2018","journal-title":"J Immunol Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13059-015-0860-5","article-title":"Genome editing: the end of the beginning","volume":"16","author":"Doudna","year":"2015","journal-title":"Genome Biol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2174\/15665232113139990026","article-title":"Genome engineering with TAL-effector nucleases and alternative modular nuclease technologies","volume":"13","author":"Scharenberg","year":"2013","journal-title":"Curr Gene Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat Rev Genet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a023754","article-title":"Genome-editing technologies: principles and applications","volume":"8","author":"Gaj","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.52586\/4997","article-title":"Research progress in gene editing technology","volume":"26","author":"Huang","year":"2021","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-026-01671-1","article-title":"Non-viral targeted integration of large DNA in primary human T cells independent of double-stranded DNA breaks","author":"Fang","year":"2026","journal-title":"Nat BioMed Eng"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1101\/2025.06.16.659978","article-title":"Prime assembly with linear DNA donors enables large genomic insertions","volume":"654","author":"Liu","year":"2026","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10395-w","article-title":"Quadruple pegRNA enables programmable and efficient large genomic insertion","volume":"654","author":"Shi","year":"2026","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B72","doi-asserted-by":"publisher","first-page":"xi12","DOI":"10.1093\/annonc\/mdz448","article-title":"35O - Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","volume":"30","author":"Lin","year":"2019","journal-title":"Ann Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020100","article-title":"Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction","volume":"141","author":"Selli","year":"2023","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2017.09.010","article-title":"CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes","volume":"636","author":"Shi","year":"2017","journal-title":"Gene"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01847-4","article-title":"The BTLA\u2013HVEM axis restricts CAR T cell efficacy in cancer","volume":"25","author":"Guruprasad","year":"2024","journal-title":"Nat Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324799","article-title":"Frontline: Neuropilin-1: a surface marker of regulatory T cells","volume":"34","author":"Bruder","year":"2004","journal-title":"Eur J Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1038\/s41467-019-11280-z","article-title":"Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1","volume":"10","author":"Leclerc","year":"2019","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0733-2","article-title":"Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity","volume":"21","author":"Liu","year":"2020","journal-title":"Nat Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adn6509","article-title":"CD5 deletion enhances the antitumor activity of adoptive T cell therapies","volume":"9","author":"Patel","year":"2024","journal-title":"Sci Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1315283","article-title":"TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells","volume":"15","author":"Cianciotti","year":"2024","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2419888122","article-title":"Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer","volume":"122","author":"Alencar","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nature11530","article-title":"BATF\u2013JUN is critical for IRF4-mediated transcription in T cells","volume":"490","author":"Li","year":"2012","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2232","article-title":"Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF","volume":"16","author":"Quigley","year":"2010","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.09.013","article-title":"Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"134.3","DOI":"10.4049\/jimmunol.202.supp.134.3","article-title":"Disruption of TOX transcription factors enhances CAR T cells function in solid tumors","volume":"202","author":"Seo","year":"2019","journal-title":"J Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"A257","DOI":"10.1136\/jitc-2022-sitc2022.0243","article-title":"243 NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo","volume":"10","author":"Lam","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113898","article-title":"NR4a1\/2 deletion promotes accumulation of TCF1(+) stem-like precursors of exhausted CD8(+) T cells in the tumor microenvironment","volume":"43","author":"Srirat","year":"2024","journal-title":"Cell Rep"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008665","article-title":"NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors","volume":"12","author":"Nakagawara","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1175","article-title":"Type I interferon signaling via the EGR2 transcriptional regulator potentiates CAR T cell-intrinsic dysfunction","volume":"13","author":"Jung","year":"2023","journal-title":"Cancer Discov"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012714","article-title":"Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy","volume":"139","author":"Yoshikawa","year":"2022","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1042\/bst20190486","article-title":"Tuning T helper cell differentiation by ITK","volume":"48","author":"Elmore","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1172\/jci178558","article-title":"IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells","volume":"135","author":"Fu","year":"2024","journal-title":"J Clin Invest"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20401","article-title":"Functional interactions of HPK1 with adaptor proteins","volume":"95","author":"Boomer","year":"2005","journal-title":"J Cell Biochem"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2016.00101","article-title":"DGK-\u03b8: structure, enzymology, and physiological roles","volume":"4","author":"Tu-Sekine","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200962","article-title":"CRISPR-Cas9 knockout of DGK\u03b1\/\u03b6 improves the anti-tumor activities of TAG-72 CAR-T cells in ovarian cancer","volume":"33","author":"Evtimov","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13023","article-title":"Regnase-1-related endoribonucleases in health and immunological diseases","volume":"304","author":"Mino","year":"2021","journal-title":"Immunol Rev"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.70","article-title":"Regnase-1, a rapid response ribonuclease regulating inflammation and stress responses","volume":"14","author":"Mao","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1821-z","article-title":"Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy","volume":"576","author":"Wei","year":"2019","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1902","article-title":"Roquin binds inducible costimulator mRNA and effectors of mRNA decay to induce microRNA-independent post-transcriptional repression","volume":"11","author":"Glasmacher","year":"2010","journal-title":"Nat Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839762","article-title":"Cooperation of RNA-binding proteins - a focus on Roquin function in T cells","volume":"13","author":"Behrens","year":"2022","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2218632120","article-title":"Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells","volume":"120","author":"Mai","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01064-3","article-title":"Disrupting Roquin-1 interaction with Regnase-1 induces autoimmunity and enhances antitumor responses","volume":"22","author":"Behrens","year":"2021","journal-title":"Nat Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116592","article-title":"The recent insights into the function of ACAT1: A possible anti-cancer therapeutic target","volume":"232","author":"Goudarzi","year":"2019","journal-title":"Life Sci"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1395192","article-title":"Targeting ACAT1 in cancer: from threat to treatment","volume":"14","author":"Sun","year":"2024","journal-title":"Front Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/nature17412","article-title":"Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism","volume":"531","author":"Yang","year":"2016","journal-title":"Nature"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-020-00796-6","article-title":"The function and regulation of TET2 in innate immunity and inflammation","volume":"12","author":"Cong","year":"2021","journal-title":"Protein Cell"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp9371","article-title":"TET2 regulates early and late transitions in exhausted CD8(+) T cell differentiation and limits CAR T cell function","volume":"10","author":"Dimitri","year":"2024","journal-title":"Sci Adv"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05692-z","article-title":"TET2 guards against unchecked BATF3-induced CAR T cell expansion","volume":"615","author":"Jain","year":"2023","journal-title":"Nature"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-20-3033","article-title":"Alterations to DNMT3A in hematologic Malignancies","volume":"81","author":"Venugopal","year":"2021","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci Transl Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adm8251","article-title":"DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity","volume":"10","author":"Li","year":"2025","journal-title":"Sci Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0126","article-title":"SUV39H1 represses the expression of cytotoxic T-lymphocyte effector genes to promote colon tumor immune evasion","volume":"7","author":"Lu","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah6499","article-title":"The epigenetic control of stemness in CD8(+) T cell fate commitment","volume":"359","author":"Pace","year":"2018","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-1319","article-title":"Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function","volume":"14","author":"Jain","year":"2024","journal-title":"Cancer Discov"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-1350","article-title":"SUV39H1 ablation enhances long-term CAR T function in solid tumors","volume":"14","author":"L\u00f3pez-Cobo","year":"2024","journal-title":"Cancer Discov"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao","year":"2024","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09212-7","article-title":"Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery","volume":"644","author":"Chen","year":"2025","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.02.012","article-title":"Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity","volume":"33","author":"Cheng","year":"2025","journal-title":"Mol Ther"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1379900","article-title":"Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells","volume":"12","author":"Cappabianca","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/nri3874","article-title":"Synchronizing transcriptional control of T cell metabolism and function","volume":"15","author":"Man","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2021.06.004","article-title":"Transcriptional regulation of T cell metabolism and metabolic control of T cell gene expression","volume":"70","author":"Veliz","year":"2021","journal-title":"Curr Opin Genet Dev"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/cells15060547","article-title":"Empowerment of CAR-T cells by IL-7 and IL-15 boosts their efficacy against HER2-positive tumors with enhanced expansion and persistence","volume":"15","author":"Cheng","year":"2026","journal-title":"Cells"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/s41467-023-37656-w","article-title":"Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-21-0801","article-title":"T cell-mediated targeted delivery of anti-PD-L1 nanobody overcomes poor antibody penetration and improves PD-L1 blocking at the tumor site","volume":"10","author":"Petit","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-0777","article-title":"Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12943-022-01712-8","article-title":"CAR T cells: engineered immune cells to treat brain cancers and beyond","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09507-9","article-title":"Systematic discovery of CRISPR-boosted CAR T cell immunotherapies","volume":"646","author":"Datlinger","year":"2025","journal-title":"Nature"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01228-9","article-title":"Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors","volume":"21","author":"Zheng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.11.011","article-title":"Turning cold into hot: emerging strategies to fire up the tumor microenvironment","volume":"11","author":"Ma","year":"2025","journal-title":"Trends Cancer"},{"key":"B139","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B140","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","article-title":"Turning cold tumors into hot tumors to ignite immunotherapy","volume":"24","author":"Liu","year":"2025","journal-title":"Mol Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102399","article-title":"In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence","volume":"6","author":"Guo","year":"2025","journal-title":"Cell Rep Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00879-x","article-title":"Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)","volume":"6","author":"Ressler","year":"2025","journal-title":"Nat Cancer"},{"key":"B144","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40425-017-0294-6","article-title":"Prospects for combined use of oncolytic viruses and CAR T-cells","volume":"5","author":"Ajina","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2013.3387","article-title":"Adjuvant intraoperative photodynamic therapy in head and neck cancer","volume":"139","author":"Rigual","year":"2013","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202403118","article-title":"Colloidal hydrogel for sensitizing microwave ablation-induced in situ tumor vaccination and modulating innate and adaptive immunotherapy","volume":"34","author":"Tian","year":"2024","journal-title":"Adv Funct Mater"},{"key":"B147","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s40425-019-0826-3","article-title":"Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine","volume":"7","author":"Turubanova","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B148","doi-asserted-by":"publisher","first-page":"e2134","DOI":"10.1038\/cddis.2016.47","article-title":"The oncolytic peptide LTX-315 triggers immunogenic cell death","volume":"7","author":"Zhou","year":"2016","journal-title":"Cell Death Dis"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1172\/jci125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"B152","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological Malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J"},{"key":"B153","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3724\/zdxbyxb-2022-0035","article-title":"Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","volume":"51","author":"Lyu","year":"2022","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107742","article-title":"CD4(+)CD25(+)CD127(low) regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"96","author":"Pan","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02766-5","article-title":"The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma","volume":"39","author":"Frede","year":"2025","journal-title":"Leukemia"},{"key":"B157","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-023-01783-1","article-title":"Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer"},{"key":"B158","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40779-023-00486-4","article-title":"Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer","volume":"10","author":"Tang","year":"2023","journal-title":"Mil Med Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13720","article-title":"Applications of single-cell omics for chimeric antigen receptor T cell therapy","volume":"171","author":"Ghaffari","year":"2024","journal-title":"Immunology"},{"key":"B160","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188818","article-title":"Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients","volume":"14","author":"Jim\u00e9nez-Ubieto","year":"2023","journal-title":"Front Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101881","article-title":"Circulating tumor DNA as a complementary prognostic biomarker during CAR-T therapy in B-cell non-hodgkin lymphomas","volume":"16","author":"Monick","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008450","article-title":"Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy","volume":"12","author":"Zou","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101237","article-title":"Clinical applications of circulating tumor DNA in hematological Malignancies: From past to the future","volume":"68","author":"Li","year":"2024","journal-title":"Blood Rev"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw3616","article-title":"Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies","volume":"372","author":"Lo","year":"2021","journal-title":"Science"},{"key":"B166","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192203","article-title":"Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J Exp Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008989","article-title":"rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors","volume":"12","author":"Li","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B169","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors","volume":"28","author":"Porter","year":"2020","journal-title":"Mol Ther"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00823-2","article-title":"FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma","volume":"31","author":"Xiao","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1910092\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:34:16Z","timestamp":1785216856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1910092\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":176,"alternative-id":["10.3389\/fimmu.2026.1910092"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1910092","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1910092"}}